These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

762 related articles for article (PubMed ID: 26576619)

  • 1. Randomized Clinical Trial of Sodium Polystyrene Sulfonate for the Treatment of Mild Hyperkalemia in CKD.
    Lepage L; Dufour AC; Doiron J; Handfield K; Desforges K; Bell R; Vallée M; Savoie M; Perreault S; Laurin LP; Pichette V; Lafrance JP
    Clin J Am Soc Nephrol; 2015 Dec; 10(12):2136-42. PubMed ID: 26576619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potassium binders for chronic hyperkalaemia in people with chronic kidney disease.
    Natale P; Palmer SC; Ruospo M; Saglimbene VM; Strippoli GF
    Cochrane Database Syst Rev; 2020 Jun; 6(6):CD013165. PubMed ID: 32588430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the tolerability and efficacy of sodium polystyrene sulfonate for long-term management of hyperkalemia in patients with chronic kidney disease.
    Georgianos PI; Liampas I; Kyriakou A; Vaios V; Raptis V; Savvidis N; Sioulis A; Liakopoulos V; Balaskas EV; Zebekakis PE
    Int Urol Nephrol; 2017 Dec; 49(12):2217-2221. PubMed ID: 29027620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium polystyrene sulfonate for the treatment of acute hyperkalemia: a retrospective study.
    Hagan AE; Farrington CA; Wall GC; Belz MM
    Clin Nephrol; 2016 Jan; 85(1):38-43. PubMed ID: 26587776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety analysis of sodium zirconium cyclosilicate and calcium polystyrene sulfonate on rapid reduction of potassium in moderate to severe hyperkalemia patients with chronic kidney disease without dialysis.
    Fu X; Zhang S; Gao F; Mao N
    Clin Nephrol; 2024 Oct; 102(4):223-231. PubMed ID: 38994592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, Controlled Trial of the Effect of Dietary Potassium Restriction on Nerve Function in CKD.
    Arnold R; Pianta TJ; Pussell BA; Kirby A; O'Brien K; Sullivan K; Holyday M; Cormack C; Kiernan MC; Krishnan AV
    Clin J Am Soc Nephrol; 2017 Oct; 12(10):1569-1577. PubMed ID: 28893921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Sodium Polystyrene Sulfonate Dosing Strategies in the Inpatient Management of Hyperkalemia.
    Mistry M; Shea A; Giguère P; Nguyen ML
    Ann Pharmacother; 2016 Jun; 50(6):455-62. PubMed ID: 27048188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term efficacy of oral calcium polystyrene sulfonate for hyperkalemia in CKD patients.
    Yu MY; Yeo JH; Park JS; Lee CH; Kim GH
    PLoS One; 2017; 12(3):e0173542. PubMed ID: 28328954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial.
    Bakris GL; Pitt B; Weir MR; Freeman MW; Mayo MR; Garza D; Stasiv Y; Zawadzki R; Berman L; Bushinsky DA;
    JAMA; 2015 Jul; 314(2):151-61. PubMed ID: 26172895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of sodium polystyrene sulfonate in the inpatient management of hyperkalemia.
    Kessler C; Ng J; Valdez K; Xie H; Geiger B
    J Hosp Med; 2011 Mar; 6(3):136-40. PubMed ID: 21387549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pretreatment of formula or expressed breast milk with sodium polystyrene sulfonate (Kayexalate(®)) as a treatment for hyperkalemia in infants with acute or chronic renal insufficiency.
    Thompson K; Flynn J; Okamura D; Zhou L
    J Ren Nutr; 2013 Sep; 23(5):333-9. PubMed ID: 23707305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient.
    Ash SR; Singh B; Lavin PT; Stavros F; Rasmussen HS
    Kidney Int; 2015 Aug; 88(2):404-11. PubMed ID: 25651363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium zirconium cyclosilicate in hyperkalemia.
    Packham DK; Rasmussen HS; Lavin PT; El-Shahawy MA; Roger SD; Block G; Qunibi W; Pergola P; Singh B
    N Engl J Med; 2015 Jan; 372(3):222-31. PubMed ID: 25415807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of pediatric hyperkalemia with sodium polystyrene sulfonate.
    Lee J; Moffett BS
    Pediatr Nephrol; 2016 Nov; 31(11):2113-7. PubMed ID: 27215929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial.
    Kosiborod M; Rasmussen HS; Lavin P; Qunibi WY; Spinowitz B; Packham D; Roger SD; Yang A; Lerma E; Singh B
    JAMA; 2014 Dec; 312(21):2223-33. PubMed ID: 25402495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.
    Weir MR; Bakris GL; Bushinsky DA; Mayo MR; Garza D; Stasiv Y; Wittes J; Christ-Schmidt H; Berman L; Pitt B;
    N Engl J Med; 2015 Jan; 372(3):211-21. PubMed ID: 25415805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the introduction of novel potassium binders in routine care; the Stockholm CREAtinine measurements (SCREAM) project.
    Gonzalez-Ortiz A; Clase CM; Bosi A; Fu EL; Pérez-Guillé BE; Faucon AL; Evans M; Zoccali C; Carrero JJ
    J Nephrol; 2024 May; 37(4):961-972. PubMed ID: 38236474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [What's new in hyperkalemia management?].
    Lefevre F; Mousseaux C; Bobot M
    Rev Med Interne; 2024 Jun; 45(6):350-353. PubMed ID: 38220492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-utility analysis of sodium polystyrene sulfonate vs. potential alternatives for chronic hyperkalemia.
    Little DJ; Nee R; Abbott KC; Watson MA; Yuan CM
    Clin Nephrol; 2014 Apr; 81(4):259-68. PubMed ID: 24656316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compared effects of calcium and sodium polystyrene sulfonate on mineral and bone metabolism and volume overload in pre-dialysis patients with hyperkalemia.
    Nakayama Y; Ueda K; Yamagishi SI; Sugiyama M; Yoshida C; Kurokawa Y; Nakamura N; Moriyama T; Kodama G; Minezaki T; Ito S; Nagata A; Taguchi K; Yano J; Kaida Y; Shibatomi K; Fukami K
    Clin Exp Nephrol; 2018 Feb; 22(1):35-44. PubMed ID: 28421299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.